Who Diagnostic Criteria For Polycythemia Vera?

Polycythemia vera (PV) is a rare blood cancer where your bone marrow makes too many red blood cells. The diagnostic criteria for polycythemia vera are specific and require either a high hemoglobin level plus one of three major criteria, or a high hemoglobin level plus all three minor criteria. A diagnosis is never made on a blood count alone; it requires a specific combination of lab values, bone marrow findings, and genetic testing.

What Are the Major Diagnostic Criteria for Polycythemia Vera?

The World Health Organization (WHO) updated the diagnostic criteria for polycythemia vera in 2016. These are the standards most hematologists use today. There are three major criteria and two minor criteria. You need either all three major criteria, or the first two major criteria plus one minor criterion.

The three major criteria are:

• High hemoglobin or red blood cell mass: Hemoglobin above 16.5 g/dL in women or above 16.5 g/dL in men. Some centers also use a hematocrit above 49% in men or 48% in women.
• Bone marrow biopsy showing too many red blood cells: The marrow shows increased cellularity for the patient’s age, with overgrowth of all three blood cell lines (red cells, white cells, and platelets).
• Presence of the JAK2 mutation: A blood test shows a mutation in the JAK2 gene — specifically JAK2 V617F or a similar mutation in exon 12.

The minor criteria are a subnormal serum erythropoietin level. Erythropoietin is the hormone that tells your bone marrow to make red blood cells. In PV, this level is usually low because the bone marrow is already overproducing red cells without needing the signal.

What Are the Minor Diagnostic Criteria for Polycythemia Vera?

There is only one minor criterion in the WHO system: a low serum erythropoietin level. When a patient has high hemoglobin and the JAK2 mutation but the bone marrow biopsy was not performed or was inconclusive, a low erythropoietin level can help confirm the diagnosis.

In practice, most patients who meet the first two major criteria also have a low erythropoietin level. The minor criterion matters most when a bone marrow biopsy is not possible, such as in a frail older patient, or when the biopsy results are unclear.

Do not confuse this with the older 2008 criteria, which required three major criteria or two major plus one minor. The 2016 update simplified the system and made the JAK2 mutation a major criterion rather than a minor one.

How Is the JAK2 Mutation Tested and Why Does It Matter?

The JAK2 V617F mutation is found in about 95% of people with polycythemia vera. Another 3-4% have a different JAK2 mutation in exon 12. This means nearly all PV patients have a detectable JAK2 mutation. A patient with high hemoglobin and no JAK2 mutation almost certainly does not have PV.

The test is a simple blood draw. It looks for the specific genetic change in your blood cells. This mutation is acquired, not inherited. It happens in a single blood stem cell and causes that cell to multiply without normal control.

Having the JAK2 mutation does not mean you have PV. Some healthy people carry the mutation without ever developing the disease. The mutation must be combined with the clinical findings — high hemoglobin, high hematocrit, and often high white blood cell and platelet counts — to make the diagnosis.

Who Diagnostic Criteria For Polycythemia Vera Apply To

The diagnostic criteria apply to adults with suspected PV. Most people are diagnosed between ages 50 and 70. The disease is slightly more common in men. Children rarely develop PV, and the criteria have not been validated in pediatric populations.

Before applying the criteria, a doctor must first rule out other causes of high hemoglobin. These include:

• Chronic lung disease
• Sleep apnea
• Living at high altitude
• Heavy smoking
• Kidney tumors that produce erythropoietin
• Congenital conditions that cause high red blood cell production

These conditions cause secondary polycythemia, which is not a blood cancer and does not carry the same risks. The JAK2 test and erythropoietin level help distinguish PV from these secondary causes. In secondary polycythemia, erythropoietin levels are typically normal or high, not low.

What Tests Are Needed to Confirm the Diagnosis?

The workup for suspected PV involves several tests done at the same time. No single test is enough. The full panel includes:

• Complete blood count: Shows hemoglobin, hematocrit, white blood cells, and platelets
• JAK2 mutation testing: Blood test for the genetic marker
• Serum erythropoietin level: Usually low in PV
• Bone marrow biopsy: Shows increased cellularity and overproduction of all blood cell lines
• Oxygen saturation: To rule out lung disease as a cause
• Abdominal ultrasound: To check for an enlarged spleen, common in PV

An enlarged spleen is a common finding in PV but is not part of the formal diagnostic criteria. It supports the diagnosis when present. About 40% of patients have an enlarged spleen at the time of diagnosis.

The bone marrow biopsy is the most invasive test but also the most informative. It shows not just too many red cells, but also overgrowth of the other cell lines. This pattern is characteristic of PV and helps distinguish it from other myeloproliferative disorders.

What Conditions Mimic Polycythemia Vera?

Several conditions can produce high hemoglobin and mimic PV. The most common are secondary causes, where another disease drives red blood cell production. Chronic hypoxia from lung disease, heart disease, or sleep apnea is a frequent culprit. Heavy smoking also raises hemoglobin.

Another group of conditions called myeloproliferative neoplasms can look similar. Essential thrombocythemia and primary myelofibrosis share some features with PV but have different diagnostic criteria. The JAK2 mutation appears in all three, so genetic testing alone cannot distinguish them. The bone marrow biopsy and blood counts are what separate them.

A rare condition called familial erythrocytosis runs in families and causes high hemoglobin without the JAK2 mutation. Genetic testing for specific inherited mutations can identify these cases. They are not cancers and do not carry the same risks as PV.

Why an Accurate Diagnosis Matters

Getting the diagnosis right changes treatment and monitoring. PV carries a risk of blood clots, stroke, and heart attack because the blood becomes thick and sluggish. It also carries a small risk of transforming into acute leukemia or myelofibrosis over many years.

People with PV are typically treated with regular phlebotomy (removing blood) to lower their hemoglobin, plus low-dose aspirin to reduce clot risk. Some patients need medication to suppress bone marrow activity. These treatments are not appropriate for people with secondary polycythemia, who need treatment of the underlying cause instead.

An incorrect diagnosis of PV leads to unnecessary phlebotomy and anxiety. A missed diagnosis of PV leaves a patient at risk for preventable blood clots. The diagnostic criteria exist to make this distinction as reliable as possible.

What Happens After Diagnosis?

Once diagnosed, PV patients are monitored regularly. Blood counts are checked every 3-6 months. The goal of treatment is to keep hemoglobin below 45% hematocrit in men and below 42% in women, based on clinical trial evidence that this reduces cardiovascular risk.

Patients are also monitored for complications. These include blood clots, bleeding, and progression of the disease. Most patients live many years with PV and manage it as a chronic condition.

Lifestyle factors matter too. Staying hydrated, avoiding smoking, and managing blood pressure and cholesterol all reduce cardiovascular risk in PV patients. Regular follow-up with a hematologist is essential.